New View Surgical, Inc. Closes $9M Series B Financing

To Fund Initial Market Release of its VisionPort™ System for Minimally Invasive Surgery

New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced that it raised $9M in a Series B financing round to fund the initial market release of its VisionPort™ System.

The Series B financing follows the company’s announcement of FDA clearance for its VisionPort System platform in June of this year. The round was led by members of New York Angels with Corza Medical, Inc., IAG Capital Partners, Charleston Angels Partners, Ariel Savannah Angel Partners, Keiretsu Forum, Mid Atlantic Bio Angels (MABA) and SSIP, among others participating in the round.

Commenting on the close of the Series B round, Bryce Klontz, President & CEO, said, “We’re excited to bring this revolutionary technology to key hospitals and surgical teams that supports our mission to advance the growth of minimally invasive surgical procedures worldwide and holistically address the clinical, operational, and financial needs of the operating room. A majority of funds raised in this round resulted from follow-on investments from current investors, which is a testament to our company’s vision and accomplishments to date.”

In conjunction with this fundraise, the New View Surgical Board of Directors will expand to include John Younger, M.D., a member of New York Angels, and Tom Testa, Chief Financial Officer at Corza Medical, Inc. Dr. Younger and Mr. Testa will serve alongside current board members, Chairman, Scott Flora, Melvin Prenovitz, Nancy Briefs, Mark Schneider and Bryce Klontz, President & CEO.

“New View Surgical is taking the bold step to reimagine laparoscopic visualization,” commented John Younger, M.D, Managing Director at ArgoPond, a life science advisory and capital firm based in Philadelphia. “The company’s game-changing visualization technology will enable less invasive surgery for patients and will make state-of-the-art visualization more accessible to surgeons, regardless of the setting. Multiple members of New York Angels participated in this round and are excited about what the future holds for New View Surgical and the VisionPort System platform,” added Tom Testa, Chief Financial Officer of Corza Medical, Inc. “New View Surgical is taking a holistic approach to adding value and is setting the stage for improved clinical care and operational efficiencies, all while lowering costs.”

Commenting on the new Board appointments, Klontz said “We are pleased to welcome John and Tom to the Board, and we are excited to welcome several new investors to the New View Surgical family.”

The VisionPort System is a novel surgical imaging and access system that simplifies laparoscopic procedures by reducing the need for a separate camera port and camera holder and allows multiple simultaneous views of the operative field. In emerging markets, the VisionPort System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, making state-of-the-art technology more accessible. The VisionPort System is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities and is adaptable to a wide variety of surgical environments, representing a significant market opportunity.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month
Micron Biomedical has received this grant from the Bill & Melinda Gates Foundation to fund mass production of needle-free vaccines utilizing Micron technology to expand the accessibility of measles-rubella vaccine in developing countries
Ann Lin, co-founder and CEO of Cromatic said, "Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”
The financing will support a substantial production capacity increase for the unique MIMIX™ hydrophilic biomaterial vascular access devices developed by AVI, which are designed to evade the foreign body reaction by mimicking the human body’s natural chemistry, as well as further research into the potential for MIMIX to lower catheter infection rates, and expansion of AVI’s product portfolio notes Access Vascular.
Neteera raised the first $13 million in April 2023 in a round led by Aescuvest, which led this extension as well. Foxconn Technology joined.

By using this website you agree to accept Medical Device News Magazine Privacy Policy